Screening & Prevention: The Checklist
Screening finds disease early. It also manufactures patients. The evidence-backed schedule for men — including the one test only men get — the PSA lesson in over-screening, and why the prevention toolkit mostly lives at home, not in the clinic.
What the evidence supports
- Colorectal, abdominal aortic aneurysm (in ever-smokers), and lung (in heavy smokers) screening each reduce disease-specific mortality in randomized trials.
- Blood pressure, lipid, and glucose checks catch the slow diseases that kill more men than any screen-detected cancer — cardiovascular disease arrives roughly a decade earlier in men.
- False positives and overdiagnosis are real, quantifiable costs — the PSA story is the worked example of what over-screening looks like.
What remains uncertain
- PSA's net benefit remains genuinely debated — the guideline trajectory from "screen everyone" to "decide together" reflects honest uncertainty, not fashion.
- Skin cancer screening has no randomized mortality evidence — the USPSTF rates the visual exam as insufficient evidence to recommend.
- The precise magnitude of overdiagnosis varies by test and model, and optimal ages and intervals remain moving targets for several tests.
Evidence last reviewed: August 13, 2026. Conclusions may change as new research is published.
the prevention checklist
Screening Is a Trade, Not a Virtue
The default assumption baked into health culture is that more tests, earlier, is always better. The evidence says otherwise. Every test trades real benefits — earlier treatment, fewer deaths — against real costs: false positives, anxiety, biopsies that find nothing, and overdiagnosis, the detection of disease that would never have caused symptoms or shortened life. A screen that finds such a cancer does not save a life; it converts a healthy man into a patient.
Men's health has lived through the loudest version of this lesson in modern medicine: the PSA era. When PSA testing went mass-market in the nineteen nineties, the expectation was simple — a blood test that catches prostate cancer early must be unambiguously good. Two decades later the accounting landed differently: roughly two in three elevated PSA results turn out not to mean cancer, an estimated one-fifth to one-half of screen-detected prostate cancers would never have caused harm, and the guidelines reversed course from "screen everyone" to "decide together." The full arithmetic lives in the Prostate & PSA topic; the lesson generalizes: the right question is never "why not test?" but "for whom, at what age, how often — and what happens to the false positives?"
The Schedule, Test by Test
The table below is the average-risk baseline — the schedule the major guideline bodies largely agree on. "Average risk" matters: family history, smoking history, and personal medical history move every row. The honest note column is the part most checklists omit.
| Test | When | Frequency | The honest note |
|---|---|---|---|
| 🫀 Blood pressure | Every checkup, from any age | At least yearly; home readings too | The single highest-value measurement in the room — cheap, silent, and directly actionable via the Blood Pressure topic |
| 🧪 Lipids & HbA1c | From the mid-thirties; earlier with risk factors | Every ~5 years; more often with risk | Men's cardiovascular curve runs roughly a decade earlier — the earlier-curve topic; panel interpretation in the Lipid Panel topic |
| 🩺 Colorectal | 45–75 | Colonoscopy every 10 yrs, or FIT yearly | The 45 start is recent (2021) — colorectal cancer is rising in younger adults; any offered modality beats none, so pick the one you will actually do |
| 🎈 Abdominal aortic aneurysm | 65–75, if you ever smoked | Once — a single ultrasound, done | The one male-specific screen: a one-time look that roughly halved AAA mortality in the randomized trial; no smoking history, no test |
| 🔍 Skin check | Per risk — fair skin, many moles, heavy sun history | Annual self-exam; clinician exam per risk | No randomized mortality evidence exists — the USPSTF rates it insufficient; sensible for high-risk men, not a universal mandate |
| 📉 PSA | 50s; mid-40s with family history or higher-risk background | Shared decision — there is no default | A decision, not a checkbox — the full trade, both columns, is in the PSA topic |
| 🫁 Lung CT (low-dose) | 50–80, with 20+ pack-year smoking history | Yearly while eligible | Only for the smoking-history group — for everyone else the false positives outweigh the benefit |
Two rows deserve the longer story. AAA: the abdominal aortic aneurysm is a ballooning of the body's main artery that kills mostly by surprise — rupture carries a death rate most estimates put above eighty percent. The randomized trial that established screening invited older men for a single ultrasound and cut aneurysm-related deaths roughly in half in the invited group, which is why the one-time test at ages sixty-five to seventy-five is reserved for ever-smokers: they carry most of the risk, and the benefit in never-smokers is too small to justify the scan. Skin: unlike every other row, visual skin checks have never been through a mortality trial, which is why the honest guidance is risk-based rather than universal — and why a self-exam habit (new or changing moles, especially one that looks different from its neighbors) costs nothing and has no false-positive bill.
The PSA Story: A Lesson in Over-Screening
The PSA timeline is the cautionary tale this whole topic is built on. In the enthusiasm era, millions of men got annual PSA tests on the assumption that earlier detection could only help. The randomized trials eventually delivered the honest arithmetic: screening does prevent some prostate cancer deaths — on the order of one to two per thousand men screened over a decade-plus — at the cost of a large biopsy cascade triggered by elevated results that mostly were not cancer. The guidelines responded: a flat "no" in 2012, then a measured "decide together" for men in their late fifties and sixties. Overdiagnosis did the damage — men treated, with side effects, for cancers that would have stayed quiet for the rest of their lives. The lesson is not anti-PSA; it is anti-default. The same discipline applies to every row in the table: know both columns before you check the box.
The Family-History Branch
Family history is the variable that moves the whole schedule earlier and denser. The table below is the pattern recognition clinicians use to decide who needs a different plan than the average-risk baseline.
| Family pattern | What it suggests |
|---|---|
| Colorectal cancer or advanced polyps in a close relative before 50 | Colonoscopy starting at 40 — or ten years before the youngest case — and more frequent follow-up |
| Prostate cancer in a father or brother | The PSA conversation starts in the mid-40s instead of the 50s — shared decision, just earlier |
| AAA in a first-degree relative | One-time ultrasound earlier than 65, even without a smoking history |
| Early heart attack or sudden cardiac death in the family | Cardiology referral and earlier, fuller lipid assessment — see the cardiovascular topic |
| Several relatives on one side with early or related cancers | A pattern, not a coincidence — a genetics referral is reasonable |
If two or more of these flags describe your family, the next step is a clinician conversation — ideally before any direct-to-consumer test, because interpretation (what a negative result does and does not rule out) matters more than the raw data. The average-risk schedule above is the right plan for a man with none of these flags; it is the wrong plan for a man with several.
The Lifestyle Layer Does the Heavy Lifting
The framing that matters most, and the reason this topic closes the Men's Health series rather than opening it: screening catches disease; prevention prevents it. Every mortality line in the table above is moved far more by what happens between checkups than by the checkup itself — which is why the ten pillars on this site are not wellness garnish; they are the actual prevention toolkit. The most under-appreciated screening system in this entire context layer is the one you keep at home: the Quarterly Audit protocol, which turns blood pressure, waist circumference, glucose trends, and sleep quality into a four-times-a-year home checkup that costs nothing and catches drift years before a clinic test would.
The honest hierarchy, stated once: the clinic schedule is worth doing — the mortality benefits are real. But the annual exam is the backstop, not the plan. A man who gets every screen on schedule but skips sleep, strength, and stress management has traded the largest prevention levers for the smallest ones. The earlier topics in this series document the specifics: strength as the survival predictor that no blood test matches, the earlier cardiovascular curve, and — the row this checklist deliberately leaves to the checkup — depression screening, covered in full in the mental health topic. The pillars are the prevention; this checklist is the safety net.
🛡️ The questions to ask before any screen
Before consenting to a test you do not obviously need, three questions change the conversation: What is my absolute risk without this screen? What happens to the false positives — how many callbacks, scans, and biopsies stand behind each case found? And what would we do differently if it came back positive? A screen whose positive result you would not act on is a screen that can only cost you. That single question has spared more men pointless procedures than any guideline.
The Bottom Line
- Screening is a trade, not a virtue — the schedule below is worth doing because the benefits are real, and worth doing on schedule because the harms grow with excess.
- The average-risk schedule: blood pressure yearly, lipids and glucose every five years from the mid-thirties, colorectal screening from age forty-five, a one-time AAA ultrasound for ever-smokers between sixty-five and seventy-five, skin checks per risk, PSA as a shared decision, and lung CT only with a heavy smoking history.
- The PSA story is the cautionary tale — mass screening manufactured patients; shared decision-making replaced the default checkbox, and the same discipline applies to every other row.
- The lifestyle layer is the prevention toolkit — screening catches disease; the ten pillars prevent it, and the quarterly audit is the home version of this checklist.
Go Deeper: Subtopics
- 🔎 The decade-by-decade map for men — what to check at 40, 50, 60, 70. Read it →
- 🔎 The PSA decision — the individualized screening conversation, made practical (links PSA topic). Read it →
- 🔎 The vascular checkup — BP, lipids, and the tests men skip most. Read it →
- 🔎 Colorectal & skin screening — the compliance gaps and the reminders that work. Read it →
- 🔎 The annual visit habit — engineering the yearly checkup into a routine that actually happens. Read it →
Related Topics
- U.S. Preventive Services Task Force, "Screening for abdominal aortic aneurysm: recommendation statement" (2019)
- U.S. Preventive Services Task Force, "Screening for colorectal cancer: recommendation statement" (2021)
- U.S. Preventive Services Task Force, "Prostate cancer: screening: recommendation statement" (2018)
- Ashton et al., "The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial," The Lancet (2002)
- National Lung Screening Trial Research Team, "Reduced lung-cancer mortality with low-dose computed tomographic screening," New England Journal of Medicine (2011)
- Schröder et al., "Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up," The Lancet (2014)